In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: Commentary

Abstract

View all access options for this article.

Goodin

Reder

Ebers

. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology 2012; 78: 1315–1322.

Espinosa

Berger

Delayed fingolimod-associated asystole. Mult Scler 2011; 17: 1387–1389.

Bourdette

Gilden

Fingolimod and multiple sclerosis: Four cautionary tales. Neurology 2012; 79: 1942–1943.

O’Connor

Wolinsky

Confavreux

. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011; 365: 1293–1303.

Fox

Miller

Phillips

. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 36: 1087–1097.

Comi

Jeffery

Kappos

. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012; 366: 1000–1009.